Acadian Asset Management
APRE icon

Acadian Asset Management’s Aprea Therapeutics APRE Stock Holding History

Acadian Asset Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-928
Closed -$91K – 1706
2021
Q2 		$91K Buy
+928
New +$85.7K ﹤0.01% 1652

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management's APRE Position: Q3 2021 in Review

Acadian Asset Management sold out of Aprea Therapeutics (APRE) in Q3 2021, closing a stake of 928 shares — an estimated $91K sold.

Acadian Asset Management first reported a position in APRE in Q2 2021 and held it in 1 quarter. The position peaked at $91K in Q2 2021. 39 funds tracked by Wall St. Rank hold APRE as of Q3 2021.

  • Acadian Asset Management reported no remaining Aprea Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Acadian Asset Management sold 928 Aprea Therapeutics shares in Q3 2021, an estimated $91K.
  • Acadian Asset Management first reported a position in Aprea Therapeutics in Q2 2021 and held it in 1 quarter.
  • Acadian Asset Management's Aprea Therapeutics position peaked at $91K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2021.

Based on Acadian Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.